Lv4
522 积分 2022-03-14 加入
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
1个月前
已完结
Leptomeningeal metastases in non-small-cell lung cancer
1个月前
已完结
The path to leptomeningeal metastasis
1个月前
已完结
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
1个月前
已完结
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
1个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
2个月前
已完结
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
2个月前
已完结
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
3个月前
已关闭
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
3个月前
已完结
皖公网安备34019202002308